Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zura Bio Limited (Nasdaq: ZURA) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, multi-asset immunology company developing novel antibodies for autoimmune and inflammatory diseases, Zura Bio uses its SEC filings to report on financial performance, risk factors, governance matters, and material corporate events.
Through periodic reports such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Zura Bio presents audited and unaudited financial statements, details on research and development expenses, general and administrative costs, cash and cash equivalents, and net losses. These filings also describe the company’s pipeline, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), and outline key risks associated with its clinical-stage status and lack of approved products.
Current reports on Form 8-K document specific material events, such as leadership transitions, executive appointments, adoption of executive severance plans, financial result announcements, and updates to corporate presentations. For example, Zura Bio has filed 8-Ks regarding changes in its chief executive officer and chief financial officer roles, the launch of investor presentations, and the release of quarterly financial results.
On Stock Titan, these filings are supplemented by AI-powered summaries that aim to explain the main points of lengthy documents, helping readers quickly identify items such as cash runway disclosures, clinical program descriptions, or changes in executive compensation arrangements. Users can also review exhibits referenced in 8-Ks, including press releases and key agreements, where available.
This page is useful for investors and researchers who want to analyze Zura Bio’s official regulatory record, track how its immunology programs are described in formal filings, and monitor governance and compensation developments over time, all with real-time updates sourced from the SEC’s EDGAR system.
Nirula Ajay reported acquisition or exercise transactions in this Form 4 filing.
Zura Bio Ltd director Ajay Nirula reported receiving a grant of 37,812 share options. These options were awarded on February 21, 2026 and vest in twelve substantially equal monthly installments over one year starting from that date. Any remaining unvested options will vest on the day immediately before the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.
Zura Bio Ltd director Ajay Nirula filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and does not report any insider purchase, sale, acquisition, or disposition transactions in the summarized data.
Zura Bio Limited filed a current report describing a press release about its Phase 2 TibuSURE study of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis. The company will present the study design as a poster at the 9th Systemic Sclerosis World Congress in Athens.
The global, randomized, double-blind, placebo-controlled Phase 2 trial is expected to enroll about 80 adults, treated every four weeks for 24 weeks, followed by a 28‑week open-label extension. The primary endpoint is change in modified Rodnan Skin Score at Week 24, with topline results anticipated in the first half of 2027.
Tibulizumab is an investigational dual-pathway antibody targeting IL-17A and BAFF. Zura highlights that no clinical efficacy or safety data will be presented in the poster; it focuses on study rationale and design only.
Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.
The shares were acquired at $6.25 per share in a registered offering by the company, increasing AI Biotechnology LLC’s direct holdings to 6,552,725 shares. Related entities, including Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, may be deemed beneficial owners through their control structure but each disclaims beneficial ownership beyond any pecuniary interest.
Zura Bio Limited’s major shareholder group updated its ownership disclosure in this Schedule 13D amendment. AI Biotechnology LLC bought 2,000,000 Class A Ordinary Shares on February 26, 2026 at $6.25 per share in a registered offering, funded with capital from affiliated entities.
After this purchase, AI Biotechnology LLC, together with related Access Industries entities and Len Blavatnik, reports beneficial ownership of 19,699,071 Class A Ordinary Shares, or 18.2% of the class. This figure includes 6,552,725 shares held directly and 13,146,346 shares issuable upon exercise of Private Placement Warrants, which are subject to a “Beneficial Ownership Blocker” that generally limits exercises above 9.99%, or up to 19.99% after notice.
Zura Bio Limited filed an amended current report to update two legal exhibits tied to a prior disclosure. Amendment No. 1 replaces in full Exhibit 5.1, the opinion of Ogier (Cayman) LLP, and Exhibit 23.1, Ogier’s consent, which were originally filed with an earlier report. The amendment states that no other portions of the original report are changed, and it lists previously filed items such as the underwriting agreement, form of pre-funded warrant, and related press releases as unchanged exhibits.
Zura Bio Limited entered into an underwriting agreement for a public offering of equity. The company is issuing 18,200,000 Class A ordinary shares at $6.25 per share and pre-funded warrants to purchase 1,800,000 ordinary shares at $6.249 per warrant.
The underwriters received a 30-day option to buy up to an additional 3,000,000 ordinary shares at the public price, and this option was exercised in full. Zura expects net proceeds of approximately $134.6 million after underwriting discounts and expenses, with closing expected on February 26, 2026, subject to customary conditions.
As of December 31, 2025, Zura estimated cash and cash equivalents of about $109.4 million. After the offering, outstanding ordinary shares are stated as 94,875,460, based on 65,018,058 shares outstanding as of September 30, 2025 and additional shares issued to Athanor Capital, assuming no exercise of the pre-funded warrants.
Zura Bio Limited is offering 18,200,000 Class A ordinary shares and pre-funded warrants to purchase 1,800,000 Class A ordinary shares. The offering is being made at a public price of
The prospectus supplement states net proceeds to the company of approximately
Zura Bio Ltd director Mark Eisner received a grant of options to acquire 37,812 shares, described as a "Share Option (Right to Buy)" at an exercise price of
The option vests in twelve substantially equal monthly installments over a one-year period starting on
Zura Bio Ltd director Mark Eisner filed an initial Form 3 ownership report. This filing identifies him as a director of Zura Bio Ltd but does not list any stock transactions or share amounts. It serves as a baseline disclosure of his status as an insider for future reporting.